Tagrisso 80 mg Alternative – Osicent (Osimertinib) 80 mg Tablet | Incepta Pharmaceuticals
Osicent 80 mg (Osimertinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Tagrisso (AstraZeneca).
Pack: 10 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Product Overview
Osicent 80 mg is listed in the supplied Lucent product catalogue. Its proposed active ingredient is Osimertinib, in tablet form. The manufacturer’s product labeling should be consulted for the final specification.
Osicent vs Tagrisso – Reference Brand Comparison
Tagrisso is a recognized reference brand associated with AstraZeneca. Osicent is listed on the supplied Lucent products price sheet, attributed by the customer to Incepta Pharmaceuticals Ltd. Matching an active ingredient does not demonstrate bioequivalence, regulatory approval or permission to substitute.
Composition and Product Details
- Listed brand: Osicent
- Generic: Osimertinib
- Strength: 80 mg
- Dosage form: Tablet
- Catalogue pack: 10 tablets
- Attributed manufacturer: Incepta Pharmaceuticals Ltd., Bangladesh
Therapeutic Uses and Indications
Osimertinib is used in selected EGFR-mutated non-small cell lung cancer. These are generic-medicine contexts, not independently confirmed approvals for this particular branded presentation. Exact eligible conditions, biomarkers and combination therapies must be confirmed from the local authorized label.
Mechanism of Action
Osimertinib inhibits selected mutant EGFR proteins. Individual treatment response depends on the disease, formulation, dosing and patient factors.
Dosage and Administration
The stated 80 mg refers to the strength of the supplied product, not a recommended daily or treatment dose. Administration schedules, preparation, food instructions and monitoring depend on the approved indication and formulation. Use only the dose and schedule prescribed by a qualified clinician. Never change strength or substitute a brand without medical advice.
Contraindications
Contraindications can include hypersensitivity and other medicine-specific conditions. Review the current prescribing information for all absolute restrictions, including relevant pregnancy-related contraindications.
Warnings and Precautions
Potential serious risks and monitoring requirements vary by medicine. Discuss infections, cardiovascular disease, liver and kidney function, other medications and pregnancy plans with the specialist. The official product leaflet determines the required safety monitoring.
Possible Side Effects
Adverse reactions may involve gastrointestinal symptoms, fatigue, laboratory abnormalities, infections or organ-specific toxicity, depending on the active ingredient. The full medicine-specific adverse effect profile, frequency and emergency warning signs must be reviewed in the authorized prescribing information.
Drug Interactions
Prescription drugs, nonprescription medicines, herbal products and some foods may interact with Osimertinib. A pharmacist or specialist should review all current medicines before treatment.
Pregnancy and Breastfeeding
Some treatments can cause fetal harm or require interruption of breastfeeding. Consult the product-specific label and treating specialist for pregnancy testing, contraception and breastfeeding guidance.
Storage and Handling
Follow the temperature, light protection, cold-chain and handling requirements printed on the actual pack. Do not assume storage conditions from another brand or formulation.
Why Is Osicent Listed as an Alternative to Tagrisso?
The comparison is provided for product discovery by active ingredient and reference brand. It does not establish pharmaceutical or therapeutic equivalence, biosimilarity, interchangeability or authorization in any country.
Manufacturer Information
Listed manufacturer: Incepta Pharmaceuticals Ltd., Bangladesh
Reference brand: Tagrisso
Reference company: AstraZeneca
Generic: Osimertinib
Strength: 80 mg
Pack: 10 tablets
Frequently Asked Questions
What does Osicent contain?
Osimertinib 80 mg, subject to confirmation against the official brand-specific label.
Is Osicent the same as Tagrisso?
No automatic equivalence or interchangeability can be inferred from the generic ingredient alone.
Can I use another strength instead?
Only when an authorized clinician specifically directs it.
Is a prescription required?
Yes. Appropriate prescription and specialist supervision are required.
Important Medical Disclaimer
Educational product identification only. Clinical information and product availability require verification against official labeling and destination-country regulatory requirements. No purchase or treatment decision should be based on this page alone.
| Generic Name | Osimertinib |
|---|---|
| Strength | 80 mg |
| Manufacturer | Incepta Pharmaceuticals Ltd. |
| Pack Size | 10 tablets |
Related products
Iressa 250 mg Alternative – Geficent (Gefitinib) 250 mg Tablet | Incepta Pharmaceuticals
Geficent 250 mg (Gefitinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Iressa (AstraZeneca).
Pack: 10 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Iressa 250 mg Alternative – Gefinix (Gefitinib) 250 mg Tablet | Beacon Pharmaceuticals
Lorbrena / Lorviqua 100 mg Alternative – Lorbrexen (Lorlatinib) 100 mg Tablet | Everest Pharmaceuticals
Lorbrexen 100 mg (Lorlatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lorbrena / Lorviqua (Pfizer). It belongs to the ALK inhibitor class and is used in selected ALK-positive metastatic non-small cell lung cancer.
Active ingredient: Lorlatinib
Strength: 100 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Retevmo / Retsevmo 40 mg Alternative – Selcaxen (Selpercatinib) 40 mg Capsule | Everest Pharmaceuticals
Selcaxen 40 mg (Selpercatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Retevmo / Retsevmo (Eli Lilly). It belongs to the RET inhibitor class and is used in selected RET-altered lung or thyroid cancers.
Active ingredient: Selpercatinib
Strength: 40 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tabrecta 200 mg Alternative – Capmaxen (Capmatinib) 200 mg Tablet | Everest Pharmaceuticals
Capmaxen 200 mg (Capmatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Tabrecta (Novartis). It belongs to the MET inhibitor class and is used in selected MET exon 14 skipping non-small cell lung cancer.
Active ingredient: Capmatinib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tarceva 100 mg Alternative – Erlonix (Erlotinib) 100 mg Tablet | Beacon Pharmaceuticals
Tarceva 150 mg Alternative – Erlonix (Erlotinib) 150 mg Tablet | Beacon Pharmaceuticals
Xalkori 250 mg Alternative – Crizocent (Crizotinib) 250 mg Capsule | Incepta Pharmaceuticals
Crizocent 250 mg (Crizotinib) Capsule is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Xalkori (Pfizer).
Pack: 12 capsules. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.

Reviews
There are no reviews yet.